Search results for "lipid A"

showing 10 items of 48 documents

Stool Phospholipid Signature is Altered by Diet and Tumors

2014

Intake of saturated fat is a risk factor for ulcerative colitis (UC) and colon cancer. Changes in the microbiota have been implicated in the development of UC and colon cancer. The host and the microbiota generate metabolites that may contribute to or reflect disease pathogenesis. We used lipid class specific quantitative mass spectrometry to assess the phospholipid (PL) profile (phosphatidylcholine [PC], phosphatidylethanolamine [PE], phosphatidylinositol [PI], phosphatidylserine [PS]) of stool from mice fed a high fat (HFD) or control diet with or without induction of colitis-associated tumors using azoxymethane and dextran sodium sulfate. The microbiota was assessed using qPCR for severa…

MaleLifestyle Causes of CancerCarcinogenesisPhysiologySaturated fatlcsh:MedicineFeceschemistry.chemical_compound0302 clinical medicineMacromolecular Structure AnalysisMedicine and Health SciencesPrevotellalcsh:SciencePhospholipids0303 health sciencesLipid AnalysisMultidisciplinaryEcologybiologyMicrobiotaCancer Risk FactorsClostridium leptumPhosphatidylserineColitis3. Good healthPhysiological ParametersOncologyBiochemistryMedical MicrobiologyNutritional Correlates of CancerColonic NeoplasmsFemale030211 gastroenterology & hepatologyAnatomyResearch Articlemedicine.medical_specialtyColonPhospholipidGastroenterology and HepatologyDiet High-FatMicrobiologyMicrobial Ecology03 medical and health sciencesInternal medicineBiomarkers TumormedicineAnimalsObesityColitisMolecular Biology030304 developmental biologyColorectal CancerPhosphatidylethanolamineAzoxymethaneBody Weightlcsh:RBiology and Life SciencesCancers and Neoplasmsmedicine.diseasebiology.organism_classificationMice Inbred C57BLGastrointestinal TractEndocrinologychemistrylcsh:QMicrobiomePhysiological ProcessesDigestive SystemPLoS ONE
researchProduct

Lipid A in Cancer Therapies Preclinical Results

2009

Studies in animal models showed that the antitumoral effect of LPS and of their biologically active moiety, lipid A, is indirect and relies on the induction of an immune response both innate and specific, leading to cytokine production. They also affect tumor development by inhibiting tumor blood flow and induce necrosis as well as apoptosis of tumor cells. Lipids A have been tested in animals, either alone or as adjuvant in therapeutic vaccines. The efficacy of treatments depends on the type of molecule and on the protocol. In general, increased survival was obtained, accompanied in some cases by tumor regression and cure.

Necrosismedicine.medical_treatmentCancerBiological activityPharmacologyBiologymedicine.diseaseLipid AImmune systemCytokineApoptosismedicinemedicine.symptomAdjuvant
researchProduct

Conclusion

2009

OncologyLipid Amedicine.medical_specialtybusiness.industryInternal medicinemedicineCancerbusinessmedicine.disease
researchProduct

Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?

2021

Antiphospholipid syndrome (APS) is frequently associated with thrombocytopenia, in most cases mild and in the absence of major bleedings. In some patients with a confirmed APS diagnosis, secondary immune thrombocytopenia (ITP) may lead to severe thrombocytopenia with consequent major bleeding. At the same time, the presence of antiphospholipid antibodies (aPL) in patients with a diagnosis of primary ITP has been reported in several studies, although with some specific characteristics especially related to the variety of antigenic targets. Even though it does not enter the APS defining criteria, thrombocytopenia should be regarded as a warning sign of a “high risk” APS and thus thoroughly ev…

Pediatricsmedicine.medical_specialtyQH301-705.5medicine.drug_classMedicine (miscellaneous)thrombocytopeniaReviewGeneral Biochemistry Genetics and Molecular BiologyAntigenimmune system diseasesAntiphospholipid syndromehemic and lymphatic diseasesmedicineBiology (General)Antiphospholipid antibodies Antiphospholipid syndrome Immune thrombocytopenia Lupus anticoagulant ThrombocytopeniaLupus anticoagulantbiologybusiness.industryAnticoagulantantiphospholipid antibodiesmedicine.diseaseThrombosisImmune thrombocytopeniaVenous thrombosislupus anticoagulantimmune thrombocytopeniabiology.proteinAntibodybusinessAntiphospholipid antibodieantiphospholipid syndromeBiomedicines
researchProduct

Enhanced in vivo targeting of murine nonparenchymal liver cells with monophosphoryl lipid A functionalized microcapsules.

2014

A broad spectrum of infectious liver diseases emphasizes the need of microparticles for targeted delivery of immunomodulatory substances to the liver. Microcapsules (MCs) are particularly attractive for innovative drug and vaccine formulations, enabling the combination of antigen, drugs, and adjuvants. The present study aimed to develop microcapsules characterized by an enhanced liver deposition and accelerated uptake by nonparenchymal liver cells (NPCs). Initially, two formulations of biodegradable microcapsules were synthesized from either hydroxyethyl starch (HES) or mannose. Notably, HES-MCs accumulated primarily in the liver, while mannose particles displayed a lung preference. Functio…

Polymers and PlasticsLiver cytologyKupffer CellsMonophosphoryl Lipid AMannoseBioengineeringCapsulesReceptors Cell SurfacePharmacologyBiomaterialsMinor Histocompatibility Antigenschemistry.chemical_compoundInterferon-gammaMiceImmune systemDrug Delivery SystemsAntigenPhagocytosisIn vivoAntigens CDMaterials ChemistryAnimalsSecretionLectins C-TypeCD40 AntigensInterleukin-6Tumor Necrosis Factor-alphaLiver DiseasesDendritic CellsIn vitroMice Inbred C57BLToll-Like Receptor 4Lipid AchemistryBiochemistryLiverNanoparticlesFemaleBiomacromolecules
researchProduct

Fucus vesiculosus extracts as natural antioxidants for improvement of physicochemical properties and shelf life of pork patties formulated with oleog…

2018

There is limited information in the literature concerning the feasibility of using algal extracts as natural additives for improvement of the quality and shelf-life ofmeat products. Hence, a Fucus vesiculosus extract (FVE) at the concentrations of 250mg kg-1 (FVE-250), 500mg kg-1 (FVE-500) and 1000mg kg-1 (FVE-1000) were added to pork patties with linseed oil oleogel as a fat replacer. RESULTS: Total polyphenol content of FVE was determined to be 20 g phloroglucinol equivalents 100 g-1 extract. Antioxidant values ranged from 37.5 𝛍mol of Trolox equivalents (TE) g-1 (FRAP assay) to 2111 𝛍mol TE g-1 extract (ABTS assay). Regarding oxidation stability, FVE-1000 showed the lowest values of th…

Seaweed extractfood.ingredientAntioxidant030309 nutrition & dieteticsFood HandlingSwinemedicine.medical_treatmentFucus vesiculosusShelf lifeSensory analysisAntioxidants03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyfoodAntioxidant activityLinseed oilmedicineAnimalsFood scienceOrganic Chemicals0303 health sciencesNutrition and DieteticsABTSbiologyPlant Extracts04 agricultural and veterinary sciencesSensory analysisbiology.organism_classificationLipid and protein oxidation040401 food scienceMeat ProductsPhysicochemical parameterschemistryFood StoragePolyphenolFucusFood AdditivesTroloxAgronomy and Crop ScienceFood ScienceBiotechnologyJournal of the science of food and agriculture
researchProduct

Structural analysis of the lipid A isolated from Hafnia alvei 32 and PCM 1192 lipopolysaccharides[S]

2010

Hafnia alvei, a Gram-negative bacterium, is an opportunistic pathogen associated with mixed hospital infections, bacteremia, septicemia, and respiratory diseases. The majority of clinical symptoms of diseases caused by this bacterium have a lipopolysaccharide (LPS, endotoxin)-related origin. The lipid A structure affects the biological activity of endotoxins predominantly. Thus, the structure of H. alvei lipid A was analyzed for the first time. The major form, asymmetrically hexa-acylated lipid A built of beta-D-GlcpN4P-(1-->6)-alpha-D-GlcpN1P substituted with (R)-14:0(3-OH) at N-2 and O-3, 14:0(3-(R)-O-12:0) at N-2', and 14:0(3-(R)-O-14:0) at O-3', was identified by ESI-MS(n) and MALDI-tim…

Spectrometry Mass Electrospray IonizationendotoxinLipopolysaccharideAcylationOligosaccharidesQD415-436BiochemistryMicrobiologyLipid Achemistry.chemical_compoundOpportunistic pathogenEndocrinologyPalmitoylationEscherichiapalmitoylationmass spectrometryPolish Collection of MicroorganismsbiologyHafnia alveiBiological activityCell Biologybiology.organism_classificationOxygenHafnia alveiLipid AchemistrySpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationlipids (amino acids peptides and proteins)BacteriaResearch ArticleJournal of Lipid Research
researchProduct

Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19

2021

Abstract Background Coronavirus disease 19 (COVID‐19)–associated coagulopathy is a hallmark of disease severity and poor prognosis. The key manifestations of this prothrombotic syndrome—microvascular thrombosis, stroke, and venous and pulmonary clots—are also observed in severe and catastrophic antiphospholipid syndrome. Antiphospholipid antibodies (aPL) are detectable in COVID‐19 patients, but their association with the clinical course of COVID‐19 remains unproven. Objectives To analyze the presence and relevance of lipid‐binding aPL in hospitalized COVID‐19 patients. Methods Two cohorts of 53 and 121 patients from a single center hospitalized for PCR‐proven severe acute respiratory syndro…

VASCULAR BIOLOGYInflammationCatastrophic antiphospholipid syndromeblood coagulation disorderendothelial protein C receptorMiceCOVID‐19immune system diseasesAntiphospholipid syndromeCoagulopathyAnimalsHumansMedicineneoplasmsEndothelial protein C receptorbiologySARS-CoV-2business.industryantiphospholipid antibodiesCOVID-19Endothelial CellsOriginal ArticlesHematologyAntiphospholipid Syndromemedicine.diseaseThrombosisinflammationImmunologyAntibodies Antiphospholipidbiology.proteinOriginal ArticleAntibodymedicine.symptomBlood coagulation disorderbusinessJournal of Thrombosis and Haemostasis
researchProduct

Etude des mécanismes d'action d'une immunothérapie par un lipide A, seul ou associé à l'oxaliplatine, dans des modèles de cancers coliques

2013

Colorectal cancer is a major public health concern in France. Resistance to standard chemotherapy requires development of novel therapeutic approaches. In the past decades, our team showed the immunotherapeutic properties of lipid A in a model of colon cancer in rats. 95% of rats bearing small carcinomas were cured following treatment by lipid A. The study of mechanisms underlying this immunotherapy allowed us to show that the antitumor effect of lipid A was dependent on cytotoxicity induced by granzyme B produced by intratumoral neutrophils. Indeed, we have shown that, in the tumor microenvironment, neutrophils produced granzyme B and had a pro-tumorigenic N2 phenotype. When rats were trea…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyNeutrophilsGranzyme BImmunothérapieNeutrophilesColon cancerLipide AOxaliplatinLipid A[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyCancer coliqueImmunotherapySénescenceOxaliplatine[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Toll-like receptors play a crucial part in the pathophysiological activity of antiphospholipid antibodies

2011

The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombosis, recurrent fetal loss and the presence of a variety of antiphospholipid antibodies (aPL), directed to phospholipids like Cardiolipin and phospholipid binding proteins like β2-glycoprotein I. Till date, the pathophysiological processes underlying these thrombotic events were still not fully understood. Recent data support the idea that the aPL might act via enhanced cytokine release due to activation of certain Toll-like receptors. The investigation of some of those mechanisms in more detail enlightens the involvement of the intracellular receptors TLR7 and TLR8 in a central point. Using patients…

business.industryAntiphospholipid antibodiesmedicine.medical_treatmentImmunologyStimulationReview ArticleTLR7medicine.diseaseMonocytesTLR2CytokineRheumatologyAntiphospholipid syndromeImmunologyTLR2MedicineTumor necrosis factor alphaSecretionTLR4businessReceptorTLR8TLR7Autoimmunity Highlights
researchProduct